NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Shisi Pharmaceutical’s three specifications of ambroxol hydrochloride injection have passed the consistency evaluation.

Category:

Group News

Time：2021-01-03

Recently, Shijiazhuang No.4 Pharmaceutical Company received the “Notice of Approval for Supplementary Drug Application” from the National Medical Products Administration, approving the following three specifications of Ambroxol Hydrochloride Injection: 1 ml: 7.5 mg, 2 ml: 15 mg, and 4 ml: 30 mg.

Recently, Shijiazhuang No.4 Pharmaceutical received the “Notice of Approval for Supplementary Drug Application” from the National Medical Products Administration, approving three specifications of Ambroxol Hydrochloride Injection: 1 ml: 7.5 mg, 2 ml: 15 mg, and 4 ml: 30 mg. All three specifications of this product have passed the evaluation of consistency in quality and efficacy with generic drugs.
It was introduced that Ambroxol Hydrochloride Injection is indicated for the treatment of acute and chronic pulmonary diseases accompanied by abnormal sputum secretion and impaired expectoration, for the prophylactic treatment of postoperative pulmonary complications, and for the treatment of infant respiratory distress syndrome in premature infants and newborns.
As of now, Shijiazhuang Fourth Pharmaceutical has had a total of 12 specifications across 8 varieties pass the National Generic Drug Quality and Efficacy Consistency Evaluation or be deemed to have passed such evaluation.